特应性皮炎患者的度普利尤单抗相关性结膜炎。

Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.

机构信息

Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; and.

Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Cornea. 2020 Jun;39(6):784-786. doi: 10.1097/ICO.0000000000002262.

DOI:10.1097/ICO.0000000000002262

PMID:31985517

Abstract

PURPOSE

To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis.

METHODS

A retrospective small case series.

RESULTS

The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation.

CONCLUSIONS

The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.

摘要

目的

报告与使用度普利尤单抗治疗特应性皮炎相关的结膜炎的发生情况。

方法

回顾性小病例系列。

结果

第一个病例是一名 56 岁男性，在开始使用度普利尤单抗 2 周后出现结膜炎。第二个病例是一名 19 岁男性，在开始使用度普利尤单抗 3 个月后出现睑结膜炎。两例患者的眼部炎症均迅速消退，且经局部皮质类固醇滴注治疗得到控制，无需停止使用度普利尤单抗。然而，在就诊时，第二位患者的 1 只眼已出现结膜瘢痕。